GMDP and psoriasis [2]

Lancet

Volumn 352, Issue 9143, 1998, Pages 1857-

  Bhushan, M ^a   McElhone, K ^a   Griffiths, C E M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MURAMYL DIPEPTIDE; N ACETYLGLUCOSAMINYL N ACETYLMURAMYL DIPEPTIDE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; GLUCOSAMINYLMURAMYL 2 ALANINE D ISOGLUTAMINE; GLUCOSAMINYLMURAMYL-2-ALANINE-D-ISOGLUTAMINE; IMMUNOLOGICAL ADJUVANT; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE;

CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; FEVER; HUMAN; LETTER; MYALGIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSORIASIS; ANALYSIS OF VARIANCE; CHRONIC DISEASE; NOTE; TREATMENT FAILURE;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ANALYSIS OF VARIANCE; CHRONIC DISEASE; HUMANS; PSORIASIS; TREATMENT FAILURE;

EID: 0032488433     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)79923-2     Document Type: Letter

References (5)

1. D Williamson M Chawla R Marks GMDP for psoriasis Lancet 352 1998 545
2. T Andronova V Ivonova The structure and immunomodulating function of glucosaminylmuramyl peptides Sov Med Rev D Immunol 4 1991 1 63
3. PCM Van de Kerkhof The Psoriasis Area and Severity Index and alternative approaches for the assessment of severity: persisting areas of confusion Br J Dermatol 137 1997 661 662
4. R Marks Measure of the response to treatment in psoriasis J Dermatol Treat 7 suppl 1 1996 S7 S10
5. T Koga K Kakimoto T Hirofuji S Kotani A Sumiyoshi K Saisho Muramyl dipeptide induces acute joint inflammation in the mouse Microbiol Immunol 30 1986 717 723